Heart failure & cardiomyopathiesGuideline or statement
EJHF expert consensus statement on the diagnosis and management of hypertrophic cardiomyopathy
- Expert consensus statement
Recommendations
As issued by the authors
Phenotypic classification, diagnosis with multimodal imaging and genetic testing, and SCD risk stratification
Pharmacologic pathways: beta-blockers, calcium channel blockers, disopyramide, cardiac myosin inhibitors (mavacamten, aficamten); indications for septal reduction therapies
Management of AF, hypertension, CAD, pregnancy, paediatric hypertrophic cardiomyopathy (HCM) and comorbidities
Controversies: optimal risk stratification models, genotype-positive/phenotype-negative individuals, exercise recommendations
Original publication
EJHF expert consensus statement on the diagnosis and management of hypertrophic cardiomyopathy. Eur J Heart Fail. Published 8 January 2026. doi:10.1093/ejhf/xuaf008
Summarised from the published abstract; every number is checked against it